KR20050121268A - 피페라진 유도체 및 신경적 및 정신적 질병의 치료를 위한그의 용도 - Google Patents

피페라진 유도체 및 신경적 및 정신적 질병의 치료를 위한그의 용도 Download PDF

Info

Publication number
KR20050121268A
KR20050121268A KR1020057019965A KR20057019965A KR20050121268A KR 20050121268 A KR20050121268 A KR 20050121268A KR 1020057019965 A KR1020057019965 A KR 1020057019965A KR 20057019965 A KR20057019965 A KR 20057019965A KR 20050121268 A KR20050121268 A KR 20050121268A
Authority
KR
South Korea
Prior art keywords
carbonyl
piperidine
isopropyl
alkyl
diazepane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020057019965A
Other languages
English (en)
Korean (ko)
Inventor
고돈 브루톤
베리 시드니 오르렉
키쇼 칼리다스 라나
Original Assignee
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0309222A external-priority patent/GB0309222D0/en
Priority claimed from GB0323109A external-priority patent/GB0323109D0/en
Application filed by 글락소 그룹 리미티드 filed Critical 글락소 그룹 리미티드
Publication of KR20050121268A publication Critical patent/KR20050121268A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020057019965A 2003-04-23 2004-04-21 피페라진 유도체 및 신경적 및 정신적 질병의 치료를 위한그의 용도 Withdrawn KR20050121268A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0309222.8 2003-04-23
GB0309222A GB0309222D0 (en) 2003-04-23 2003-04-23 Novel compounds
GB0323109.9 2003-10-02
GB0323109A GB0323109D0 (en) 2003-10-02 2003-10-02 Novel compounds

Publications (1)

Publication Number Publication Date
KR20050121268A true KR20050121268A (ko) 2005-12-26

Family

ID=33454571

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057019965A Withdrawn KR20050121268A (ko) 2003-04-23 2004-04-21 피페라진 유도체 및 신경적 및 정신적 질병의 치료를 위한그의 용도

Country Status (23)

Country Link
US (1) US7592347B2 (enExample)
EP (1) EP1615909B1 (enExample)
JP (1) JP2006528939A (enExample)
KR (1) KR20050121268A (enExample)
AR (1) AR044045A1 (enExample)
AT (1) ATE402165T1 (enExample)
AU (1) AU2004238447C1 (enExample)
BR (1) BRPI0409611A (enExample)
CA (1) CA2523431A1 (enExample)
CO (1) CO5700754A2 (enExample)
DE (1) DE602004015269D1 (enExample)
DK (1) DK1615909T3 (enExample)
ES (1) ES2311152T3 (enExample)
HR (1) HRP20080541T3 (enExample)
IS (1) IS8134A (enExample)
MA (1) MA27675A1 (enExample)
MX (1) MXPA05011352A (enExample)
PL (1) PL1615909T3 (enExample)
PT (1) PT1615909E (enExample)
RU (1) RU2005136368A (enExample)
SI (1) SI1615909T1 (enExample)
TW (1) TW200503713A (enExample)
WO (1) WO2004101546A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
EP1768959A2 (en) 2004-06-28 2007-04-04 Janssen Pharmaceutica N.V. Hetero isonipecotic modulators of vanilloid vr1 receptor
HRP20080227T3 (hr) * 2004-10-15 2008-06-30 Glaxo Group Limited Pirolidinski derivati kao ligandi histaminskih receptora
US7635705B2 (en) 2005-06-20 2009-12-22 Schering Corporation Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
CA2609957A1 (en) 2005-06-20 2007-01-04 Schering Corporation Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
EP1899296B1 (en) 2005-06-22 2010-11-17 Pfizer Products Inc. Histamine-3 receptor antagonists
WO2007016496A2 (en) 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
EP1931665A1 (en) 2005-09-20 2008-06-18 Schering Corporation 1-[[1-[(2-amin0-6-methyl-4-pyridinyl)methyl]-4-flu0r0-4-piperidinyl,]carbonyl]-4-[2-(2-pyridinyl)-3h-imidaz0[4, 5-b]pyridin-3-yl]piperidine useful as histamine h3 antagonist
AR058558A1 (es) 2005-12-21 2008-02-13 Schering Corp Derivados de anilina sustituida utiles como antagonistas de la histamina h3
CA2634250A1 (en) 2005-12-21 2007-07-05 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
BRPI0712823A2 (pt) 2006-06-23 2012-07-24 Abbott Lab derivados de ciclopropil amina como moduladores de receptor de histamina h3
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
WO2008108957A2 (en) * 2007-03-02 2008-09-12 Schering Corporation Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain
TW200902007A (en) * 2007-05-25 2009-01-16 Astrazeneca Ab Spirocyclopropyl piperidine derivatives
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
ES2350511T3 (es) 2007-06-11 2011-01-24 F. Hoffmann-La Roche Ag Derivados ciclohexilo.
TW201446748A (zh) 2007-08-22 2014-12-16 Astrazeneca Ab 環丙基醯胺衍生物
CL2008002622A1 (es) 2007-09-06 2009-11-27 Glaxo Group Ltd 1-(1-metiletil)-4-{[4-(tetrahidro-2h-piran-4-iloxi)fenil]carbonil}piperazina y su sal hidrocloruro; formas cristalinas de la sal; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento o profilaxis de deterioro cognitivo, fatiga o trastorno del sueno.
US20100130477A1 (en) * 2008-11-25 2010-05-27 Astrazeneca Ab Spirocyclobutyl Piperidine Derivatives
EA020548B1 (ru) 2008-12-19 2014-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US9186353B2 (en) * 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
ME01908B (me) 2009-12-17 2014-12-20 Boehringer Ingelheim Int Novi antagonisti ccr2 receptora i njihova primjena
SG183231A1 (en) * 2010-02-18 2012-09-27 Astrazeneca Ab Solid forms comprising a cyclopropyl amide derivative
NZ602110A (en) * 2010-02-18 2014-09-26 Astrazeneca Ab Processes for making cyclopropyl amide derivatives and intermediates associated therewith
US8877745B2 (en) 2010-05-12 2014-11-04 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011141477A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
WO2011147772A1 (en) 2010-05-25 2011-12-01 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
EP2731941B1 (en) 2011-07-15 2019-05-08 Boehringer Ingelheim International GmbH Novel and selective ccr2 antagonists
AR088256A1 (es) 2011-10-08 2014-05-21 Novartis Ag Derivados de carbamato / urea como antagonistas del receptor h3
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
US9034874B2 (en) 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives
AU2016287584B2 (en) 2015-07-02 2020-03-26 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
JP2025511097A (ja) * 2022-03-31 2025-04-15 廣州必貝特醫藥股▲ふん▼有限公司 １，４－ジヘテロシクリル置換芳香環若しくは芳香族複素環系化合物及びその使用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0745121B1 (en) * 1992-05-14 2007-06-20 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US5364791A (en) * 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
GB9526546D0 (en) 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
KR20000029984A (ko) * 1996-08-14 2000-05-25 사라 엔 람베쓰 치환된피리미딘유도체및이의약학적용도
EP1058549A4 (en) * 1998-12-23 2003-11-12 Bristol Myers Squibb Pharma Co FACTOR Xa OR THROMBIN INHIBITORS
US6683093B2 (en) * 2000-05-12 2004-01-27 Pharmacia Corporation Aromatic sulfone hydroxamic acids and their use as protease inhibitors
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
CA2432825A1 (en) * 2000-12-15 2002-06-20 Emory University Nonpeptide agonists and antagonists of vasopressin receptors
US6849621B2 (en) 2001-03-13 2005-02-01 Schering Corporation Piperidine compounds
WO2002076925A2 (en) 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
ATE449090T1 (de) 2001-07-02 2009-12-15 High Point Pharmaceuticals Llc Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
ATE479655T1 (de) 2001-09-14 2010-09-15 High Point Pharmaceuticals Llc Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
ATE450508T1 (de) 2001-09-14 2009-12-15 High Point Pharmaceuticals Llc Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
JPWO2003062234A1 (ja) 2002-01-23 2005-05-19 山之内製薬株式会社 キノキサリン化合物
NZ535764A (en) 2002-04-18 2007-10-26 Schering Corp 1-(4-piperidinyl) benzimidazolones as histamine H3 antagonists
PT1499316E (pt) 2002-04-18 2008-06-30 Schering Corp Derivados de (1-4-piperidinil)benzimidazole úteis como antagonistas de histamina h3
EP1554260A1 (en) 2002-10-22 2005-07-20 Glaxo Group Limited Aryloxyalkylamine derivatives as h3 receptor ligands

Also Published As

Publication number Publication date
HRP20080541T3 (en) 2008-12-31
CA2523431A1 (en) 2004-11-25
AU2004238447C1 (en) 2009-06-11
WO2004101546A1 (en) 2004-11-25
EP1615909A1 (en) 2006-01-18
JP2006528939A (ja) 2006-12-28
HK1090634A1 (en) 2006-12-29
DK1615909T3 (da) 2008-11-17
AU2004238447B2 (en) 2008-10-30
ATE402165T1 (de) 2008-08-15
EP1615909B1 (en) 2008-07-23
DE602004015269D1 (de) 2008-09-04
SI1615909T1 (sl) 2008-12-31
RU2005136368A (ru) 2006-06-10
PL1615909T3 (pl) 2009-01-30
CO5700754A2 (es) 2006-11-30
US20070054917A1 (en) 2007-03-08
IS8134A (is) 2005-11-21
MXPA05011352A (es) 2005-11-28
US7592347B2 (en) 2009-09-22
BRPI0409611A (pt) 2006-04-18
ES2311152T3 (es) 2009-02-01
PT1615909E (pt) 2008-10-30
TW200503713A (en) 2005-02-01
AR044045A1 (es) 2005-08-24
AU2004238447A1 (en) 2004-11-25
MA27675A1 (fr) 2005-12-01

Similar Documents

Publication Publication Date Title
KR20050121268A (ko) 피페라진 유도체 및 신경적 및 정신적 질병의 치료를 위한그의 용도
JP4824567B2 (ja) 新規化合物
RU2423353C1 (ru) Новые производные бензазепина
JP4679509B2 (ja) ２，３，６−置換−４−ピリミドン誘導体
ES2303280T3 (es) Derivados de pirrolidina como ligandos de receptores de histamina.
WO2005087746A1 (en) Benzazepine derivatives for the treatment of neurological and psychiatric disorders
US20060247227A1 (en) Substituted piperidines as histamine h3 receptor ligands
KR20050111638A (ko) 알츠하이머병을 비롯한 신경계 질환의 치료를 위한히스타민 ｈ3 길항제로서의4-(4-(헤테로시클릴알콕시)페닐)-1-(헤테로시클릴-카르보닐)피페리딘 유도체 및 관련 화합물
US7638631B2 (en) Methylene dipiperidine derivatives
JP2008509955A (ja) ヒスタミンｈ３受容体のアンタゴニストおよび／または逆アゴニストとしてのテトラヒドロベンズアゼピン
JP4943858B2 (ja) 芳香族アミド誘導体、それを含有する医薬組成物およびそれらの医薬用途
CA2589831A1 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
KR20070113225A (ko) 히스타민 ｈ３ 수용체에 대해 친화성을 갖는 융합된 티아졸유도체
HK1090634B (en) Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
WO2004056821A2 (en) Quinolizidine derivatives
CN101115721A (zh) 茚基衍生物和它们在治疗神经疾病中的用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20051021

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid